Roche aims to 'underwhelm' on SMA drug price to challenge rivals
January 14, 2020 at 04:32 AM EST
Swiss drugmaker Roche plans to price its oral spinal muscular atrophy drug (SMA) risdiplam aggressively to challenge two of the world's most expensive medicines, Biogen's Spinraza and Novartis's gene therapy Zolgensma.